Completed PHASE2 INTERVENTIONAL 1-arm NCT00500110

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Neoadjuvant Hormonal Ablation, Imatinib Mesylate and Docetaxel Followed by Radical Prostatectomy for High-Risk Localized Prostate Cancer

Sponsor: M.D. Anderson Cancer Center

Conditions Prostate Cancer

Interventions Docetaxel Goserelin Acetate Imatinib Mesylate Leuprolide

Updated 5 times since 2017 Last updated: Apr 6, 2015 Started: Jun 30, 2003 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 5 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States